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Abstract  
Aim: To investigate the immunomodulatory potential of a chimera composed of the receptor-binding 
domain of hemagglutinin 1 (H1s) from Influenza virus and Der p 2 (D2) allergen for allergen-specific 
immunotherapy of house-dust mite allergy (HDM).  
Main methods: H1sD2 chimera and D2 allergen were produced by genetic engineering in E. coli. 
Recombinant antigens were extracted from inclusion bodies by urea, then refolded and purified by 
immobilized- metal affinity chromatography (IMAC). Purity was verified by 2D-PAGE and secondary 
structures were assessed by CD spectroscopy. IgE reactivity of H1sD2 and D2 was tested in western blot 
with sera from 8 persons with clinical history of HDM allergy. Immunogenicity of H1sD2 and D2 were 
analyzed in Balb/c mice. Cytokine profile was analyzed by ELISA after stimulation of mouse spleen cells 
with H1sD2 and D2. Leukocyte population abundance of cells isolated from spleen and lymph node was 
assessed by flow cytometry. 
Key findings: Purified recombinant proteins H1sD2 (42 kDa) and D2 (15 kDa) revealed well defined 
secondary structures, and preserved IgE reactive epitopes. Analysis of supernatants of mouse spleen cells 
after stimulation with H1sD2 and D2, revealed a qualitatively different cytokine profile from H1sD2 
immunized mouse cells (increase in IL10). CD8+ cells were decreased in the lymph node of D2 
immunized mice, whereas H1sD2 immunization led to an increase of CD8+ cells in both the lymph node 
and the spleen. 
Significance: H1sD2 chimera attenuates Der p 2-inherent Th2 response and directs the immune response 
toward Th1 and Treg phenotype. 
 
Key words: allergy, house dust mites, vaccine, immunotherapy 
 
1. Introduction  
Allergy represents a chronic non-communicable disease with increasing prevalence worldwide 
(approximately 30% to 40 % of the world population) [1,2]. It is an IgE mediated immune disorder 
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characterized by Th2 phenotype which develops against innocuous environmental antigens in genetically 
predisposed (atopic) persons. Clinical manifestations of an allergic response are triggered when allergen 
binds and cross-links specific IgE antibodies anchored for high affinity IgE receptor (FcRI) on the 
effector cells (mast cells and basophils) which then release biologically active mediators (histamine, 
leukotrienes, prostaglandins, cytokines). The only therapeutic option with curative effect in allergic 
patients is allergen-specific immunotherapy (AIT). AIT was introduced by Noon [3] more than a century 
ago and it is still the only disease-modifying treatment in allergy. AIT induces reduction of clinical 
symptoms and prevents the development of asthma and new allergen sensitizations, by the introduction of 
defined amounts of allergen to an allergic patient for a certain period of time.  
AIT is predominantly performed with allergen extracts which besides disease-causing allergens contain 
nonallergenic components with adjuvant activity that can drive the immune response via a Th2 pathway 
[4,5] and consequently can contribute to elicitation of IgE sensitization to other allergens present in the 
extract. In addition, variations in content and amounts of individual allergens in allergen extracts can 
compromise efficacy of AIT. To improve safety and efficacy of the therapeutic approach, replacement of 
allergen extracts with defined amounts of recombinant allergens has been proposed as an alternative [6]. 
Good clinical efficacy was reported in clinical trials conducted with recombinant allergen preparations 
(timothy grass pollen, birch pollen) in comparison to placebo. Therapeutic treatment is mainly associated 
with modification of the specific immune response in terms of promotion of specific IgG4 and reduction 
of specific IgE antibodies, together with the induction of IL-10-producing regulatory T cells [7].  
However, in spite of beneficial clinical efficacy, recombinant allergen preparations revealed poor 
immunogenicity, and therefore they do not induce significantly better therapeutic effects than natural 
extracts [8,9]. Moreover, there is a need for employment of novel immunomodulators capable to enhance 
the innate immune response in order to economically justify the production of recombinant allergy 
vaccines [10].  
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House dust mite is a well-known cause of respiratory allergic disease worldwide. Also, diagnosis and 
treatment is still a challenge [11]. AIT in house dust mite allergy has been shown to correct the 
underlying allergic cause safely and effectively, with long-term effect after the end of treatment [12,13]. 
According to their molecular properties mite allergens are classified in 24 groups, but almost 80-90% of 
mite-allergic persons are sensitized to Der p 1 and Der p 2 [14]. While biologically active Der p 1 
(cysteine protease) can compromise barrier of the bronchial epithelium, allowing allergens and 
nonallergic components to reach cells of the immune system, Der p 2 has an immunoglobulin-like tertiary 
structure around a hydrophobic cavity [15] which can have an intrinsic adjuvant effect due to its proposed 
LPS binding abilities and contributes to the allergenicity of such molecules [16]. It has been found that 
Der p 2 reveals structural homology with MD-2
 
and shows auto-adjuvant properties which contributes to 
allergic sensitization [16].  
Influenza is one of the major infectious diseases of the human population. Viral infections, including the 
influenza A virus infection, generally produce a cytokine milieu that favors the development of type 1 
immunity [17]. Influenza vaccines provide the most effective control of seasonal outbreaks [18]. The key 
protective antigen in natural immunity and vaccines of Influenza virus is the envelope-associated 
hemagglutinin (HA) [19]. It is the surface glycoprotein inserted into the lipid bilayer as spike, which 
promotes virus entry into the cells. The HA is a trimeric glycoprotein made of a globular receptor-binding 
domain (RBD) settled onto a stem domain [20]. 
Modulation of the immune response toward Th1 profile in the context of house dust mite allergy has 
already been explored. For instance, bacilli Calmette-Guerin (rBCG), a vaccine strain against tuberculosis 
as a strong inducer of Th1 response had been used as a delivery vehicle for the presentation of foreign 
antigens to the immune system. Inoculation of recombinant rBCG with Der p 2 cause a Th1-type immune 
response that corrects Der p 2 induced allergic sensitization and consequent development of airway 
inflammation [21] .  
In this study immunodominant epitope of HA1 was exploited as modulator for reshaping inherent Th2 
response of Der p 2. In a previous study we have showed that a chimera composed of the native sequence 
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of the receptor-binding domain and a part of stalk segment of HA1 heamagglutinih (HA63–351) and Der 
p 2 revealed immunomodulatory potential in a mouse model (Balb/ c) [22]. By intranasal application of 
H1D2, reduced levels of D2 specific IgE and increased D2 specific IgG and IgA were detected. In 
addition, a higher level of effectors CD4+CD25+ spleen lymphocytes were also observed in a group of 
mice which received i.n. instillations of H1D2.  
In this study we redesigned H1D2 chimera to obtain better solubility by excluding the stalk domain and 
coupling only the receptor-binding domain of H1 with Der p 2. Immunogenicity of the novel chimera 
H1sD2 produced by the recombinant DNA technology was tested in Balb/ c mice.  
2. Materials and methods  
2.1 Design of H1sD2 chimera  
A model of the H1sD2 chimera was designed form the crystal structure of a 2009 H1N1 influenza virus 
hemagglutinin, PDB entry 4M4Y [23] (chain A from amino acid residue 54 to 276 with original PDB 
residue numbering is used), and structure of the major house dust mite allergen Der p 2, PDB entry 1A9V 
[24] (model 1 from the NMR structure is used), in a similar way as it was previously described [25], but 
with the following changes. The original H1D2 construct was shortened for 60 amino acids (part of stalk 
domain) from the C terminus of H1 hemagglutinin. The resulting H1sD2 is composed of 371 amino acids 
which encodes for the HA receptor-binding domain (HA63-291), linker PGPG, and Der p 2 with the 6His 
tag on C terminus.  
A proline-glycine-proline-glycine (PGPG) hinge is created between H1s and D2 to prevent steric 
hindrance, while a 6His tag is added at the C-terminus of the D2 protein for the purification purpose. The 
PGPG linker is modeled as a -turn and the 6His tag as a -strand. The computer-generated H1sD2 
chimeric structure is obtained by connecting the four segments and adding the hydrogen atoms in 
Discovery Studio [26] followed by a full structural minimization in NAMD 2.9 [27] with CHARMM22 
force field in implicit solvent/water model for 50 ps. The structure obtained this way is relaxed and strain-
free without any bond and torsion angle constrains and van der Waals clashes. The short linker part 
efficiently prevents the non-bonded interactions between the two main domains, H1s and D2, by keeping 
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them distant. Therefore, their tertiary structures and binding sites remain intact and available for the 
immune system. The structure of the 6His tag already possesses His residues in a favorable orientation 
such that can easily get coordinated to Co
2+
 cations. Final structure of the H1sD2 chimera is shown in Fig. 
1A, and the amino acid sequence is presented in Fig. 1B. Depiction is made in Discovery Studio [26].  
 
Fig. 1. Design of H1sD2 chimera: (A) modeled structure of H1sD2; (B) schematic illustration of the 
creation of H1sD2. H1s segment is shown in orange, Der p 2 in yellow, PGPG linker in blue and the 6His 
tag in green color.  
  
2.2 Strains and plasmids  
Escherichia coli strains DH5α (Invitrogen Thermo Fisher Scientific, Carlsbad, USA) and BL21-
CodonPlus (DE3)-RIPL (Agilent Technologies Inc., La Jolla, USA) were employed as host either for 
propagation of plasmid pET23b (Merck Millipore, Merck KGaA, Darmstadt, Germany) or for expression 
of recombinant D2 and H1sD2 proteins, respectively. Bacteria were grown in LB medium supplemented 
with antibiotics.  
2.3 Expression, purification and refolding of the recombinant antigens  
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pET23b vector was used for expression of Der p 2 and H1sD2 genes. Recombinant protein was produced 
in BL21-CodonPlus (DE3)-RIPL cells as previously described [22].  
Gene coding for H1D2 [22] was used as a template for creation of H1sD2 construct. Briefly, DNA 
sequence of H1s and of Der p 2 were amplified by PCR with the following primers: H1s for 5´-
CTAGCTAGCATGGGTGTTGCCCC-3´, H1s rev 5´-ACGCGTCGACTGTATTCATATCGTGAAC-3´ 
with restriction sites for Nhe I and Sal I; Der p 2 for 5´-ACGCGTCGACCCAGGTCCGGGTG-3´, Der p 
2 rev 5´-CCGCTCGAGATCACGGATTTTAGCATGAG-3´ with restriction sites for Sal I and Xho I. The 
cloning strategy introduced 6His tag to the C terminus. After cut with respective restriction enzymes both 
PCR products were ligated into pET23b resulting in the generation of H1sD2 construct. OFR was 
confirmed by DNA sequencing.  
Expression of H1sD2 gene has been done in BL21-CodonPlus (DE3)-RIPL cells in LB medium (10 g L
-1 
tryptone, 5 g L
-1
 yeast extract, 5 g L
-1
 NaCl) containing 100 mg L
-1
 ampicillin, 25 mg L
-1
 kanamicin and 
25 mg L
-1
 chloramphenicol. 5 mL of overnight culture was inoculated into 1 L of sterile medium with 
antibiotics at 37
o
C. When absorbance (OD600) reached 0.7, medium temperature was lowered to room 
temperature and isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the final concentration of 1 
mmol L
-1
. Cells were grown at room temperature overnight in a shaking incubator.  
Upon collection and lysis of H1sD2 and D2 expression cells, inclusion bodies were extensively washed in 
Lysis buffer (50 mmol L
-1
 Tris pH 8.0, 100 mmol L
-1
 NaCl) and afterward were solubilized in Lysis 
buffer with 8 M urea, overnight at 4 °C. Refolding and purification were done as in [22]. After gel 
electrophoresis, fractions of purified protein were pulled and applied to endotoxin removal column 
(Pierce™ High Capacity Endotoxin Removal Spin Columns, 0.5 mL). Briefly, 4-6 mL of pulled fractions 
were mixed with 0,5 mL of endotoxin removal matrix in batch and incubated for 1 h. Protein solution was 
eluted and dialyzed afterwards against PBS (phosphate buffered saline). After dialysis fractions were 
centrifuged, filtered and used for immunizations.  
2.4 2D PAGE  
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The homogeneity of purified recombinant D2 and H1sD2 were analyzed by 2D PAGE according to [28]. 
In brief, the sample (25 g) was resolved under native conditions by isoelectric focusing in 5% (w/v) 
polyacrylamide gel containing 2.4% (v/v) ampholytes (pH 3.5-10, Pharmacia). Following separation in 
the first dimension, the gel stripe with respective recombinant protein was incubated in equilibration 
buffer (62.5 mmol L
-1
 Tris-HCl, 5 % 2-mercaptoethanol, 2.5 % SDS, 10 % glycerol) for 15 min and then 
run in the second dimension on SDS-PAGE (13 %). D2 and H1sD2 were visualized following staining 
with Coomassie Brilliant Blue. 
2.5 CD spectroscopy  
Circular dichroism (CD) spectroscopy was used to evaluate the overall conformation of refolded D2 and 
H1sD2 proteins. Spectra were recorded at 25 °C on a Jasco J-815 A spectrophotometer (Jasco, Japan). 
Measurements in the far-ultraviolet region (185-260 nm) were performed in 0.5 mm path length on 
protein samples (0.767 and 0.375 mg mL
-1 
for D2 and H1sD2, respectively) dialyzed overnight against a 
20 mmol L
-1
 Tris buffer, pH 8.0. Spectra represent the average of three accumulations and were baseline-
corrected by subtraction of blank buffer. Data was collected at rate of 50 nm min
-1
 with integration time 
of 4 s. 
2.6 IgE reactivity of recombinant proteins  
IgE reactivity of recombinant D2 and H1sD2 were analyzed in immunoblot with serum from eight house 
dust mite allergic persons. The study was performed with the approval of the Ethics Committee of the 
University Children's Hospital of Belgrade, Serbia (Approval No. 017-990/87/2012-01/19) in accordance 
to Serbian National guidelines (which follow the Declaration of Helsinki) for studies involving human 
subjects. Informed written consent was obtained prior to the study. IgE reactivity of both antigens in 
immunoblot was detected as previously described [22].  
2.7 Animals and immunization protocol 
In this experiment 8 week old female Balb/c mice (Military Medicine Academy, VMA, Belgrade, Serbia), 
were used. All experiments were approved by the Ethics Committee for the welfare of experimental 
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animals, at the Institute of Virology, Vaccines and Sera, Torlak, Serbia, and conformed to Serbian laws 
and European regulations on animal welfare (Directive 2010/63/EU; Approval No. 323-07-01577/2016-
05/13).  
At days 0 and 14 mice from experimental groups (n=6), were immunized by intramuscular (i.m.) injection 
of 2×50 μL of antigens in PBS, protein amount was 12.5 μg of D2 or H1sD2. Age control group received 
PBS only. On days 21 mice were anesthetized and bled for serum collection and on day 35 mice were 
terminated by cervical dislocation, and spleens and inguinal lymph nodes were collected.   
2.8 Evaluation of allergen-specific antibodies in mouse serum  
MaxiSorp ELISA plates (Nunc A/S, Denmark) were coated overnight at 4 °C with 5 μg/mL of purified 
D2 allergen in 0.1 M sodium carbonate buffer (pH 9.6). Blocking was done with PBS/2% BSA (1 h, 37 
°C), the wells were filled with 100 fold diluted mice sera (in PBS containing 1% BSA), for both IgG and 
IgG2a and incubated for 1h at RT. Anti-mouse IgG-HRP (dilution 1:10 000, Jackson ImmunoResearch 
Laboratories Inc., WestGrove, PA, USA) and anti-mouse IgG2a-biotin (dilution 1:1000, Biolegend) 
followed by streptavidin-HRP (Biolegend) was used for detection with o-phenylenediamine as the 
substrate.  
2.9 Leukocyte extraction and flow cytometry  
Mouse spleens were removed, trimmed of excess tissue and mashed in 5 mL RPMI 1640 (cat no. R4130, 
Sigma-Aldrich) supplemented with 2 gL
-1
 sodium bicarbonate, 10 U/mL Penicillin/Streptomycin and 10% 
fetal calf serum FCS (complete RPMI). Separately mouse inguinal lymph nodes were extracted, mashed 
and placed in complete RPMI. Both types of cell suspensions were passed through sterile steel mesh to 
remove large particles and centrifuged at 400 × g (Heraeus Megafuge 16R, Thermo Scientific). Pellets 
were resuspended and erythrocyte-depleted by incubation in 2 ml Lysis buffer (150 mM NH4Cl, 10 mM 
NaHCO3, 1 mM disodium EDTA) for 10 min. After centrifugation (400 × g, 10 min), cells were placed in 
complete RPMI.  
For flow cytometry cell suspension was diluted in 2% BSA in PBS with 0.1% sodium azide to 1×10
6
 
cells/mL. Antibodies used for cell typing were directed against CD3ε (145-2C11, Hamster IgG, FITC), 
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CD25 (PC61.5.3, Rat IgG1, FITC), CD19 (PeCa1 Rat IgG2a PE) and CD8a (YTS 169.4, Rat IgG2b, PE), 
all purchased from Immunotools (Immunotools, Friesoythe, Germany). After incubation (20 min, 4 °C, 
dark) 2 mL 2% BSA in PBS with 0.1% sodium azide was added, vortexed and centrifuged (400 × g for 10 
min); this step was repeated twice and the cells were finally suspended in PBS with 0,4% formaldehyde. 
The signal was analyzed with FACSVerse (Becton Dickinson, Mountain View, CA, USA). Lymphocyte 
gate was used for the estimation of population abundance. 
2.10 Cell stimulation and cytokine secretion analysis 
Spleen cells of experimental mice (2×10
6/mL) were stimulated with 6 μg/mL of either D2 or H1sD2, for 
48h and supernatants were collected and stored at -80°С.  
In supernatants, levels of IFNγ, IL4, IL5, and IL10 were measured in ELISA sandwich assay. Antibodies 
and standards were purchased from Biolegend (San Diego, CA), and were used according to the 
manufacturer recommendations. All washing steps included 3× washings with TPBS, and one wash with 
PBS. The coloured substrate was either 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (Sigma-
Aldrich St. Louis, MO, USA) or o-phenylenediamine (Sigma-Aldrich, St. Louis, MO, USA). The 
absorbance was measured at 405 or 492 nm (reference wavelength 620 nm).  
2.11 Statistical analysis  
Statistical analysis of cytokine and antibody levels between the experimental groups, as well as graphical 
presentation was performed with Origin software. Statistical analysis of lymph node and spleen 
lymphocyte percentages between the experimental groups, as well as graphical presentation was 
performed with Graph Pad software. One-way ANOVA with Tukey test for means comparison between 
the groups was used. Data is expressed as mean ± SEM. P<0.05 was considered significant. 
3. Results  
3.1 Expression and isolation of H1sD2  
To analyze immunomodulatory potential of hemagglutinin from influenza A virus in house dust mite 
allergy the chimera H1sD2 made of the receptor-binding domain of hemagglutinin (HA63-291, GenBank 
GQ149630) from influenza A (H1N1) and Der p 2 allergen (GenBank JN222809) was designed. In total 
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371 amino acids long, H1sD2 is 60 amino acids shorter from previously designed H1D2 chimera, lacking 
a part encoding for the stalk domain of H1 spike.  
The H1sD2 chimera was produced in E. coli with 6His tag and after extraction from inclusion bodies and 
refolding; H1sD2 was purified under native conditions by Co
2+
 metal affinity chromatography. The 
chimera revealed one spot in 2D PAGE (Fig. 2A) with molecular mass of about 42 kDa and theoretical pI 
6.6. 
Protocol for extraction of D2 from inclusion bodies and downstream purification was similar as for 
H1sD2. D2 revealed one spot in 2D PAGE (Fig. 2B) stained by CBB with molecular mass of 15 kDa and 
theoretical pI 6.6. 
 
Fig. 2. Purified H1sD2 and D2 were separated by isoelectric focusing according to pI value, and then 
according to molecular weight in 13% SDS PAGE and stained with CBB R250. A) 2D PAGE of H1sD2 
B) 2D PAGE of D2. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
12 
 
 
3.2 CD spectra analysis  
Secondary structures of purified D2 and H1sD2 were analyzed by CD spectrometry (Fig. 3). CD spectra 
of D2 revealed minimum at about 215 nm and maximum at 197 nm. The shape of CD spectra revealed β-
sheeted secondary structures of D2, in agreement with the literature data [29]. H1sD2 also revealed 
minimum at 215 nm which indicated presence of β-sheets. 
 
Fig. 3. CD spectra of recombinant D2 and H1sD2 in the far-ultraviolet region (185-260 nm).  
 
3.3 IgE immunoblot analysis of H1sD2 and D2 
To test IgE reactivity recombinant D2 and H1sD2 were transferred onto a nitrocellulose membrane and 
were incubated with sera from eight persons with medical history of house dust mite allergy. Levels of 
specific IgE in patients sera to HDM allergens were as follows: class 6 (> 100.01 kUA/L) in person’s no. 
2, 3 and 6; class 5 (50.01 - 100.0 kUA/L) in person’s no. 1, 4, 7 and 8; and class 4 (17.51 - 50.00 kUA/L) 
in person 5 as determined with the ImmunoCAP System (Thermo Fisher Scientific/Phadia, Uppsala, 
Sweden). The relative intensity of IgE reactive bands for H1sD2 and D2 were comparable (Fig. 4). The 
most IgE reactive sera were from person’s no. 2, 3, 5, and 6 for H1sD2. Similar pattern of IgE reactivity 
was found for recombinant D2 allergen, except for serum no. 2 which revealed weak IgE reactivity in 
comparison to H1sD2. Due to the limited amount of no. 2 serum an additional analysis was not performed 
to clarify this discrepancy. 
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Fig. 4. IgE reactivity of sera from HDM allergic persons to H1sD2 and D2 (No. 1-8); k –control of the 
secondary antibody (monoclonal anti-human IgE-AP). Level of HDM specific IgE in individual sera were 
assessed by ImmunoCAP (No. 1 – class 5; No. 2 - class 6; No. 3 – class 6; No. 4 – class 5; No. 5 – class 
4, No. 6 – class 6, No. 7 – class 5; No. 8 – class 5). 
3.4 Production of D2 specific antibodies 
The levels of D2 specific IgG and IgG2a were assessed with ELISA. While higher specific IgG was 
detected in mice injected with D2, levels of IgG2a were higher in H1sD2 injected animals (not shown). 
The differences between the experimental groups were not statistically significant. Nevertheless, it should 
be emphasized that in terms of moles of antigens employed for immunization of mice 3.4 times D2 (1.04 
nmol) was higher when compared to H1sD2 (0.305 nmol). 
 
3.5 Cytokine production  
As shown in Fig. 5 the control group (PBS injected) showed basal levels of cytokines production, with no 
production of IL-5, or IFN-γ, and the stimulation with either antigen did not raise the level of these 
cytokines. The production of these cytokines were highest in D2 injected group, stimulated with H1sD2 
for IL-5, and the highest IFN-γ level was produced in H1sD2 injected/stimulated group, though this result 
was not statistically significant due to high deviation. The cells of H1sD2 injected mice also produced 
highest levels of IL-10, upon stimulation with H1sD2. There was no increase in production of IL-4 
instead the basal level was reduced by stimulation with D2, and even further with H1sD2.  
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Fig. 5. Levels of different cytokines measured from splenocyte cultures supernatants, obtained from mice 
immunized with PBS, D2 or H1sD2, after 48h of incubation with different stimulators. Samples from 
non-stimulated cells – NS, upon stimulation with 6 g/mL of Der p2 – D2 or 6 g/mL H1sD2 chimera – 
H1sD2. A) IFN-γ; B) IL-4; C) IL-5; D) IL-10. Mean values ± SEM are shown, and statistical significance 
was assessed by ANOVA test, and P<0.05 is a limit of statistical significance. Statistical significance 
shown is obtained by comparing levels for the same stimulator between differently immunized groups. 
 
3.6 Spleen and lymph node cell population analysis  
Leukocytes extracted from spleens and inguinal lymph node of mice immunized with H1sD2, D2 and 
PBS, respectively, were analyzed by flow cytometry. A slight increase was noted in CD19+ cell count 
following D2 injection in both the spleen and lymph node, but this increase was not statistically 
significant (Fig. 6). Concomitantly a slight decrease in CD3+ cell count in both compartments were 
found, but this also lacked statistical significance, as did the differences in CD25+ cells. Significant 
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differences were found in the abundance of CD8+ cells, and these were location specific, such that the 
CD8+ cells were decreased in the lymph node of D2 immunized mice, whereas H1sD2 immunization led 
to an increase of CD8+ cells in both the lymph node and the spleen.  
 
Fig. 6. Differences in spleen and lymph node lymphocyte population abundance analyzed upon day 35 
from the beginning of the experiment. The data represent mean values ± SEM from three biological 
replicates, each made by pooling samples from two mice. Statistical significance was determined with use 
of Graph Pad software and One-way ANOVA test, P<0.05 was considered significant. Different 
superscripts mark statistical significance between different groups. 
4. Discussion  
Allergy vaccines which are based on purified or recombinant antigens are usually poorly immunogenic 
and require additional components to promote protective immunity. Very often adjuvants are employed to 
promote the immune response towards the purified or recombinant vaccines, which can reduce the 
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number of doses required to achieve protection [30]. Viral infections, including those induced by 
influenza A virus provides cytokine phenotype of type 1 immunity [17], including the production of 
strong humoral response dominantly of IgG and IgA classes. Haemagglutinin A (HA) is the spike 
glycoprotein on influenza virus envelope, which binds to the receptor on host epithelial cells to invade it. 
As a source of immunodominant epitopes its immunogenicity has been employed in design of the first 
recombinant influenza vaccine FluBlok® approved by the FDA, which is composed of a trivalent 
recombinant hemagglutinin.  
The H1sD2 chimera produced in E. coli was purified from inclusion bodies by 8 M urea. After refolding 
the chimera revealed well defined secondary structure as well as D2 antigen, both analyzed by CD 
spectrometry. Computational analysis of the modeled H1sD2 chimeric structure also supports the finding 
that H1s and D2 domains generally retain their secondary and tertiary structure. Besides, the H1sD2 
chimera showed better solubility in aqueous solutions than the previously designed H1D2 chimera, which 
additionally contains stalk domain decorated with high number of nonpolar amino acids. Improved 
solubility of the novel chimera allowed employing immunization protocol of animals without aluminium 
hydroxide, which per se possess a Th2-biasing effects [31]. Both antigens preserved IgE reactivity in 
immunoblot when tested with serum form house dust mite allergic persons, showing that IgE epitopes are 
present on the newly constructed chimera. Although western blot is not a quantitative method, the 
discrepancy in the intensity of IgE reactivity between D2 and H1sD2 was noticed for serum no. 2. Animal 
experiments were performed in order to evaluate the immunomodulatory effect of the chimera H1sD2, 
composed of the receptor-binding domain (RBD) of hemagglutinin 1 and Der p 2 allergen, and to 
compare it with recombinant Der p 2. Immunization protocol was designed in such a way to assess 
immunogenicity, and the type of the obtained response.  
Findings accumulated in the last decade shed more light on the contribution of the innate immunity in the 
pathogenesis of type I hypersensitivity. Epithelial-derived cytokines and chemokines also orchestrate the 
innate immune cells (basophils, mast cells, eosinofils, macrophages) to sustain the Th2 priming [32,33]. 
In the context of HDM allergy it has been clearly shown that it is not purely dys-regulation of the 
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adaptive immunity. A tight connection between the innate and adaptive immunity is important for the 
initiation and propagation of the Th2 allergic response. Der p 2 has been known for some time as a trigger 
of the innate immune response. Its interactions with pattern-recognition receptors such as TLR2 [34] and 
TLR4 [16] activates distinct signaling pathways and lead to the production of inflammatory cytokines 
and/or type I IFNs. Here a population of splenic cells was used, which in mice consist mainly of 
lymphocytes (50-60% CD19+ cells or B cells and 30-40% CD3+ cells or T cells) as it is convenient for 
assessing antigen specific responses. The differences in quantity and quality of cytokine production are 
known to exist between different cell types and myeloid cells, representing innate immunity, are different 
to lymphocytes representing adaptive immunity in this respect.  
Cell stimulation experiment clearly showed that H1sD2 induces a qualitatively different type of response 
as compared to D2. While D2 led to an increase of IL-5 and a decrease of IL-4, H1sD2 increased IL-10, 
and IFN-γ, leading to a conclusion that H1sD2 induced activation was more potent, and comprised of Th1 
and Treg compartment activation as well. The changes found in cell population abundance, especially a 
significant increase in CD8
+
 cells in the spleen of H1sD2 immunized animals support the conclusion of 
Th1 response activation [35].  
No significant differences were noted in specific antibody production upon immunization with D2 and 
H1sD2 antigens without adjuvant. This may be due to a relatively small number of animals used and 
partly due to a small number of doses. The chimera designed and produced here induces roughly the same 
amount of IgG in immunized animals, even though 3.4 times less moles of the chimera were used. 
Allergen specific immunotherapy, which is in use as an only curative approach, works by increasing 
protective IgG4 in humans, which is one of the parameters measured when monitoring progress of 
allergen specific immunotherapy [36]. In addition, influenza vaccine per se induces different kinds of 
protective response depending on the formulation [37]. Also, the reactivity of hemagglutinin chimeras in 
humans would be influenced by the preexisting immunity to the influenza virus [38,39]. As evidenced 
from the results presented here soluble chimeric antigen is able of inducing qualitatively different 
responses as well, which is seen when comparing D2 to H1sD2. 
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5. Conclusion 
In this study the aqueous-soluble H1sD2 chimera was designed, produced and its 
immunogenicity tested in mice which revealed potential for the modulation of the immune 
response toward Th1 and Treg phenotype. With such a chimera, without use of adjuvants, 
induction of Der p 2-inherent Th2 immune response was attenuated in a mouse model. This 
finding indicates that H1sD2 chimera can be an interesting candidate for application in 
modulating the immune response in house dust mite allergy. 
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Figure captions 
Fig. 1. Design of H1sD2 chimera: (A) modeled structure of H1sD2; (B) schematic illustration of the 
creation of H1sD2. H1s segment is shown in orange, Der p 2 in yellow, PGPG linker in blue and the 6His 
tag in green color.  
Fig. 2. Purified D2 and H1sD2 were separated by isoelectric focusing according to pI value, and then 
according to molecular weight in 13% SDS PAGE and stained with CBB R250. A) 2D PAGE of H1sD2; 
B) 2D PAGE of D2. 
Fig. 3. CD spectra of recombinant D2 and H1sD2 in the far-ultraviolet region (185-260 nm).  
Fig. 4. IgE reactivity of sera from HDM allergic persons to H1sD2 and D2 (No. 1-8); k –control of the 
secondary antibody (monoclonal anti-human IgE-AP) . Level of HDM specific IgE in individual sera 
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were assessed by ImmunoCAP (No. 1 – class 5; No. 2 - class 6; No. 3 – class 6; No. 4 – class 5; No. 5 – 
class 4, No. 6 – class 6, No. 7 – class 5; No. 8 – class 5). 
Fig. 5. Levels of different cytokines measured from splenocyte cultures supernatants, obtained from mice 
immunized with PBS, D2 or H1sD2, after 48h of incubation with different stimulators. Samples from 
non-stimulated cells – NS, upon stimulation with 6 g/mL of Der p2 – D2 or 6 g/mL H1sD2 chimera – 
H1sD2. A) IFN-γ; B) IL-4; C) IL-5; D) IL-10. Mean values ± SEM are shown, and statistical significance 
was assessed by ANOVA test, and P<0.05 is a limit of statistical significance. Statistical significance 
shown is obtained by comparing levels for the same stimulator between differently immunized groups. 
Fig. 6. Differences in spleen and lymph node lymphocyte population abundance analyzed upon day 35 
from the beginning of the experiment. The data represent mean values ± SEM from three biological 
replicates, each made by pooling samples from two mice. Statistical significance was determined with use 
of Graph Pad software and One-way ANOVA test, P<0.05 was considered significant. Different 
superscripts mark statistical significance between different groups 
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